Literature DB >> 29130984

Lymphocyte Cell Ratios and Mortality among Incident Hemodialysis Patients.

Christina Catabay1, Yoshitsugu Obi1, Elani Streja1,2, Melissa Soohoo1, Christina Park1, Connie M Rhee1, Csaba P Kovesdy3,4, Takayuki Hamano5, Kamyar Kalantar-Zadeh1,2,6.   

Abstract

BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been previously suggested as oncologic prognostication markers. These are associated with malnutrition and inflammation, and hence, may provide benefit in predicting mortality among hemodialysis patients.
METHODS: Among 108,548 incident hemodialysis patients in a large U.S. dialysis organization (2007-2011), we compared the mortality predictability of NLR and PLR with baseline and time-varying covariate Cox models using the receiver operating characteristic curve (AUROC), net reclassification index (NRI), and adjusted R2.
RESULTS: During the median follow-up period of 1.4 years, 28,618 patients died. Median (IQR) NLR and PLR at baseline were 3.64 (2.68-5.00) and 179 (136-248) respectively. NLR was associated with higher mortality, which appeared stronger in the time-varying versus baseline model. PLR exhibited a J-shaped association with mortality in both models. NLR provided better mortality prediction in addition to demographics, comorbidities, and serum albumin; ΔAUROC and NRI for 1-year mortality (95% CI) were 0.010 (0.009-0.012) and 6.4% (5.5-7.3%) respectively. Additionally, adjusted R2 (95% CI) for the Cox model increased from 0.269 (0.262-0.276) to 0.283 (0.276-0.290) in the non-time-varying model and from 0.467 (0.461-0.472) to 0.505 (0.500-0.512) in the time-varying model. There was little to no benefit of adding PLR to predict mortality.
CONCLUSIONS: High NLR in incident hemodialysis patients predicted mortality, especially in the short-term period. NLR, but not PLR, added modest benefit in predicting mortality along with demographics, comorbidities, and serum albumin, and should be included in prognostication approaches.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Chronic hemodialysis; End-stage kidney disease; Hemodialysis; Inflammation; Lymphocyte; Mortality; Neutrophil; Nutrition; Platelet

Mesh:

Substances:

Year:  2017        PMID: 29130984      PMCID: PMC5777311          DOI: 10.1159/000484177

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  40 in total

Review 1.  Chronic inflammation links cardiovascular, metabolic and renal diseases.

Authors:  Ichiro Manabe
Journal:  Circ J       Date:  2011-11-08       Impact factor: 2.993

2.  From COPD to chronic systemic inflammatory syndrome?

Authors:  Leonardo M Fabbri; Klaus F Rabe
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

3.  Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction.

Authors:  Kamyar Kalantar-Zadeh; Ryan D Kilpatrick; Noriko Kuwae; Charles J McAllister; Harry Alcorn; Joel D Kopple; Sander Greenland
Journal:  Nephrol Dial Transplant       Date:  2005-06-14       Impact factor: 5.992

4.  Lack of correlation between total lymphocyte count and nutritional status in the elderly.

Authors:  Masafumi Kuzuya; Shigeru Kanda; Teruhiko Koike; Yusuke Suzuki; Akihisa Iguchi
Journal:  Clin Nutr       Date:  2005-06       Impact factor: 7.324

5.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.

Authors:  J Zimmermann; S Herrlinger; A Pruy; T Metzger; C Wanner
Journal:  Kidney Int       Date:  1999-02       Impact factor: 10.612

6.  Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients.

Authors:  George A Kaysen; Joel A Dubin; Hans-Georg Müller; Laura Rosales; Nathan W Levin; William E Mitch
Journal:  Kidney Int       Date:  2004-04       Impact factor: 10.612

7.  Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.

Authors:  Deborah L Regidor; Csaba P Kovesdy; Rajnish Mehrotra; Mehdi Rambod; Jennie Jing; Charles J McAllister; David Van Wyck; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 10.121

8.  C-reactive protein as an outcome predictor for maintenance hemodialysis patients.

Authors:  W F Owen; E G Lowrie
Journal:  Kidney Int       Date:  1998-08       Impact factor: 10.612

9.  Platelet-to-lymphocyte ratio predicts mortality better than neutrophil-to-lymphocyte ratio in hemodialysis patients.

Authors:  Mustafa Yaprak; Mehmet Nuri Turan; Ramazan Dayanan; Selçuk Akın; Elif Değirmen; Mustafa Yıldırım; Faruk Turgut
Journal:  Int Urol Nephrol       Date:  2016-04-27       Impact factor: 2.370

10.  What is the normal value of the neutrophil-to-lymphocyte ratio?

Authors:  Patrice Forget; Céline Khalifa; Jean-Philippe Defour; Dominique Latinne; Marie-Cécile Van Pel; Marc De Kock
Journal:  BMC Res Notes       Date:  2017-01-03
View more
  16 in total

1.  Acute kidney injury as an independent predictor of infection and malignancy: the NARA-AKI cohort study.

Authors:  Miho Tagawa; Masatoshi Nishimoto; Maiko Kokubu; Masaru Matsui; Masahiro Eriguchi; Ken-Ichi Samejima; Yasuhiro Akai; Kazuhiko Tsuruya
Journal:  J Nephrol       Date:  2019-10-15       Impact factor: 3.902

2.  Association of neutrophil-to-lymphocyte ratio and risk of cardiovascular or all-cause mortality in chronic kidney disease: a meta-analysis.

Authors:  Guangyu Ao; Yushu Wang; Xin Qi; Fengping Wang; Huitao Wen
Journal:  Clin Exp Nephrol       Date:  2020-10-06       Impact factor: 2.801

3.  The clinical significance of neutrophil-lymphocyte ratio in patients treated with hemodialysis complicated with lung infection.

Authors:  Ling-Lin Li; Yu-Qiong Yang; Min Qiu; Li Wang; Hong-Ling Yuan; Ren-Chao Zou
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

4.  The Clinical Utility of the Neutrophil-to-Lymphocyte Ratio as a Discriminatory Test among Bacterial, Mycobacterium Tuberculosis, and Nontuberculous Mycobacterium Peritoneal Dialysis-Related Peritonitis.

Authors:  Winston Wing-Shing Fung; Kai-Ming Chow; Jack Kit-Chung Ng; Gordon Chun-Kau Chan; Philip Kam-Tao Li; Cheuk-Chun Szeto
Journal:  Kidney360       Date:  2022-03-29

5.  The Predictive Value of NLR, MLR, and PLR in the Outcome of End-Stage Kidney Disease Patients.

Authors:  Adrian Vasile Mureșan; Eliza Russu; Emil Marian Arbănași; Réka Kaller; Ioan Hosu; Eliza Mihaela Arbănași; Septimiu Toader Voidăzan
Journal:  Biomedicines       Date:  2022-05-29

6.  The relationship between vitamin D and inflammatory markers in maintenance hemodialysis patients.

Authors:  Ali Veysel Kara; Yasin Emrah Soylu
Journal:  Int Urol Nephrol       Date:  2019-08-05       Impact factor: 2.370

7.  Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in evaluation of inflammation in non-dialysis patients with end-stage renal disease (ESRD).

Authors:  Peiyuan Li; Chenqi Xia; Peng Liu; Zhong Peng; Hong Huang; Juan Wu; Zhangxiu He
Journal:  BMC Nephrol       Date:  2020-11-25       Impact factor: 2.388

8.  The prognostic value of the ratio of neutrophils to lymphocytes before and after intensity modulated radiotherapy for patients with nasopharyngeal carcinoma.

Authors:  Jing Liu; Changwu Wei; Haijun Tang; Yun Liu; Wenqi Liu; Chengsen Lin
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

9.  Neutrophil-to-lymphocyte ratio in relation to the risk of all-cause mortality and cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Wen-Man Zhao; Shu-Man Tao; Gui-Ling Liu
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

10.  Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Nondialysis Chronic Kidney Patients.

Authors:  Gysllene M C Brito; Andrea M M Fontenele; Erika Cristina R L Carneiro; Iara Antonia L Nogueira; Tamires B Cavalcante; André A M Vale; Sally Cristina M Monteiro; Natalino Salgado Filho
Journal:  Int J Inflam       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.